RxSight (RXST) Gains from Investment Securities (2020 - 2021)

RxSight (RXST) posted Gains from Investment Securities of $5.4 million for Q4 2021, up 461.54% on a QoQ basis from -$1.5 million in Q3 2021, and up 115.49% year-over-year from $2.5 million in Q4 2020.

RxSight (RXST) Gains from Investment Securities (2020 - 2021) Analysis & Trends

RxSight's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $5.4 million for Q4 2021.

  • Quarterly Gains from Investment Securities rose 115.49% year-over-year to $5.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2022 was $5.4 million (up 116.79% YoY) and the FY2025 annual result came in at $1.5 million, up 113.74% from the prior year.
  • Gains from Investment Securities was $5.4 million for Q4 2021 at RxSight, up from -$1.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.4 million in Q4 2021 and bottomed at -$39.5 million in Q3 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 183.85 Bn 176.55 Bn 6.27 Bn
2 Stryker 128.90 Bn 126.02 Bn 3.81 Bn
3 Medtronic 108.55 Bn 99.33 Bn 6.41 Bn
4 Boston Scientific 68.56 Bn 67.10 Bn 3.61 Bn
5 Edwards Lifesciences 48.24 Bn 44.57 Bn 1.29 Bn
6 Dexcom 28.40 Bn 27.28 Bn 750.30 Mn
7 GE HealthCare Technologies 28.15 Bn 25.87 Bn 1.98 Bn
8 Smith & Nephew 26.89 Bn 26.31 Bn -
9 Koninklijke Philips 24.75 Bn 21.63 Bn 2.07 Bn
10 RxSight 224.91 Mn -193.30 Mn 23.50 Mn

Historic Data

Download Data
DateValue
Dec 31, 2021 5.43 Mn
Dec 31, 2021 5.43 Mn
Sep 30, 2021 -1.50 Mn
Sep 30, 2021 -1.50 Mn
Jun 30, 2021 -1.21 Mn
Jun 30, 2021 -1.21 Mn
Dec 31, 2020 -35.08 Mn
Dec 31, 2020 -35.08 Mn
Sep 30, 2020 -39.52 Mn
Sep 30, 2020 -39.52 Mn
Jun 30, 2020 4.18 Mn
Jun 30, 2020 4.18 Mn